Maggie L. Shaw

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those with higher BSA, a new study finds.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.

Those who developed primary open-angle glaucoma (POAG) had lower mental health scores compared with those who had not developed the condition.

Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) who currently rely on frequent phlebotomies for relief.

New research reveals mental health recovery post COVID-19 takes nearly 3 times longer than physical health, highlighting the need for targeted care strategies.

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the disparities and potential solutions in obesity care.

Trump's sweeping health care overhaul faces scrutiny, risking coverage for millions while igniting bipartisan tensions over fiscal and social impacts.

With the FDA approval of retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, researchers are now focusing on resistance mechanisms and future therapies, according to Sheela Rao, MBBS, MD, FRCP, of The Royal Marsden Hospital.

Research reveals low awareness and usage of the 988 crisis lifeline, highlighting disparities in support for LGBTQ+ individuals and regional funding challenges.

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

In the US, individuals die during pregnancy and the postpartum period at a greater and increasing rate than in any other high-income country.

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

To truly shift the landscape in obesity care, explains Jaime Almandoz, MD, MBA, UT Southwestern, care models and policies must also consider quality of life and total health outcomes.

Systemic barriers beyond just the price of drugs can impact health care costs, emphasizing the need for comprehensive affordability solutions, explained H. John Beardsley, MBA, of CoverMyMeds, and Fauzea Hussain, MPH, of McKesson.

Global type 1 diabetes cases are on the rise, especially in low-income countries, highlighting an urgent need for targeted health care strategies and epidemiological studies.

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

Gary Falcetano, PA-C, AE-C, explains that proactively managing seasonal allergies can significantly decrease the overall inflammatory burden, thereby improving both physical symptoms and potentially mitigating neuroinflammation's impact on mental well-being.

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 Vibrance-MG study investigator, he explains the difficulty of evaluating investigative treatments for pediatric patients who have myasthenia gravis.

US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to report fair or poor health, underscoring persistent disparities in worker well-being.

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

The landscape of treatment for bronchiectasis could change significantly with the approval of brensocatib, offering a more direct method of stemming the adverse events related to the condition, explains James Chalmers, MD, University of Dundee.

Molecular testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, significantly improving disease-free survival rates post-surgery.

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking financial stability and patient access to care.

Combining FRAX and MG-ADL assessments enhances fracture risk prediction in patients with myasthenia gravis (MG), guiding targeted interventions for better outcomes.

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.